☆ 4.6 Review

Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy

CANCERS (2023)

Related references

Note: Only part of the references are listed.

Article Radiology, Nuclear Medicine & Medical Imaging

Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients Receiving Concomitant 225Ac-DOTATATE-Targeted a-Therapy and Capecitabine: A Real-World-Scenario Management-Based Long-Term Outcome Study

Sanjana Ballal et al.

Summary: This study evaluated the long-term outcome of 225Ac-DOTATATE targeted alpha therapy (TAT) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors. The results showed that the therapy was effective, even in patients refractory to prior treatment, with acceptable adverse effects.

JOURNAL OF NUCLEAR MEDICINE (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden

Denise A. Gococo-Benore et al.

Summary: The aim of this study was to assess the risk of liver toxicity in patients with gastroenteropancreatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy (PRRT) with a very high liver tumor burden. The results showed that only one out of fifteen patients with more than 75% liver involvement experienced liver function deterioration, with no clinical signs of liver failure. Therefore, PRRT may be considered a safe option for patients with extensive liver involvement.

JOURNAL OF NUCLEAR MEDICINE (2023)

Add to Collection

Article Endocrinology & Metabolism

Australasian consensus statement on the identification, prevention and management of hormonal crises in patients with neuroendocrine neoplasms (NENs) undergoing peptide receptor radionuclide therapy (PRRT)

Minmin Li et al.

Summary: Hormonal crises following PRRT in NENs patients are rare but increasingly recognised. Inconsistent approaches to identification, prevention and management of risk factors exist due to limited published studies. This consensus statement aims to provide guidance based on clinical demand and concerns, and involves collaboration of experts from Australia and New Zealand.

NEUROENDOCRINOLOGY (2023)

Add to Collection

Article Oncology

Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score

David L. Chan et al.

Summary: This study validates the NETPET score as a prognostic biomarker in metastatic GEPNENs, capturing the complexity of dual PET imaging.

BRITISH JOURNAL OF CANCER (2023)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response-AJR Expert Panel Narrative Review

Samuel J. Galgano et al.

Summary: Neuroendocrine neoplasms (NENs) are a diverse group of tumors with various treatment options. Precise criteria for treatment response in NENs are lacking and different imaging modalities have different strengths and weaknesses in evaluating therapy response. Further definition of standardized assessment criteria for tumor response and progression is needed.

AMERICAN JOURNAL OF ROENTGENOLOGY (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

The Quest for an Accurate Functional Tumor Volume with 68Ga-DOTATATE PET/CT

Ryan P. Reddy et al.

Summary: Ga-68-labeled somatostatin analog PET/CT is a standard component in the management of neuroendocrine tumors. However, the assessment of treatment response for these tumors still relies on morphologic size measurements, which may not accurately reflect the disease burden. This study aimed to test the accuracy of different methods for measuring functional tumor volume (FTV) using PET/CT and identify a reliable method for assessing tumor burden. The results showed that FTV determined with a thresholding approach had the strongest correlation with traditional morphologic volume measurements, indicating its potential use in determining disease extent and prognosis in patients with neuroendocrine tumors.

JOURNAL OF NUCLEAR MEDICINE (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors

Ur Metser et al.

Summary: In patients with SSTR-RADS 5 PM-NETs treated with Lu-177-DOTATATE, all lesions with PET-generated Krenning score >= 2 showed similar response to therapy. There was no correlation between lesion's diameter and level of tracer uptake.

NUCLEAR MEDICINE COMMUNICATIONS (2022)

Add to Collection

Article Oncology

Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas

Arvind Dasari et al.

Summary: Treatment patterns in gastrointestinal neuroendocrine carcinoma vary based on stage and primary tumor site. Surgical resection significantly improves survival in patients with early stages and shows a strong trend in advanced stages, regardless of the tumor location.

ONCOLOGIST (2022)

Add to Collection

Article Oncology

Predictive and Prognostic Role of Pre-Therapy and Interim 68Ga-DOTATOC PET/CT Parameters in Metastatic Advanced Neuroendocrine Tumor Patients Treated with PRRT

Rexhep Durmo et al.

Summary: This study aimed to identify biomarkers derived from 68Ga-DOTATOC PET/CT in patients undergoing PRRT. The results showed that high baseline total tumor volume (bTV) is a negative predictor for PRRT response and is associated with worse overall survival rates. Integrating bTV as an imaging biomarker in the initial assessment of NET patients could improve risk stratification and contribute to a tailored therapy approach.

CANCERS (2022)

Add to Collection

Review Oncology

Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors

Valentina Ambrosini et al.

Summary: Neuroendocrine neoplasms (NENs) are rare and heterogeneous tumors that require multidisciplinary discussion for optimal care. The theranostic approach plays a crucial role in the management of NENs, but further research is needed to verify its effectiveness.

CANCERS (2022)

Add to Collection

Review Oncology

Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms

Amir Iravani et al.

Summary: Neuroendocrine neoplasia (NEN) is a disease group that includes well-differentiated neuroendocrine tumors (NETs) and aggressive neuroendocrine carcinomas (NECs). The site of origin of NENs is linked to the tumor biology and predicts the disease course. NENs exhibit significant biological heterogeneity, leading to varying clinical presentations, disease courses, and prognosis. Therefore, the evaluation of markers that can predict tumor behavior and monitor treatment response is crucial in NEN therapy.

CANCER IMAGING (2022)

Add to Collection

Article Oncology

Post-PRRT scans: which scans to make and what to look for

Else A. Aalbersberg et al.

Summary: This study aimed to evaluate the clinical utility of SPECT/CT and planar imaging in post-PRRT imaging for neuroendocrine tumor patients. The results showed that thoracoabdominal SPECT/CT imaging was the preferred method, while planar imaging had no added value. For patients with abdominal disease only on baseline imaging, abdomen-only SPECT/CT imaging might be sufficient. All accompanying CT images should be reviewed for additional findings, especially ascites, which is suggested to be a poor prognostic factor in patients receiving PRRT.

CANCER IMAGING (2022)

Add to Collection

Article Endocrinology & Metabolism

Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors

Marta Opalinska et al.

Summary: This study aimed to investigate whether changes in SUVmax value on [68Ga]Ga-DOTA-TATE PET/CT scans could serve as a potential predictor of long-term response to PRRT. The results showed that a decrease in SUVmax value in NET lesions, corrected by normal liver tissue uptake, indicated a lower risk for NET progressive disease within 20 months after PRRT.

FRONTIERS IN ENDOCRINOLOGY (2022)

Add to Collection

Article Oncology

[68Ga]Ga-DOTANOC Uptake at Pancreatic Head/Uncinate Process: Is It a Persistent Diagnostic Pitfall Over Time?

Elena Tabacchi et al.

Summary: This study describes the frequency of non-malignant [68Ga]Ga-DOTANOC uptake in the pancreatic head/uncinate process (UP) and evaluates its variations over time. The findings show that UP uptake is common, mostly diffuse, and exhibits variations over time in almost one third of the cases. Awareness of this diagnostic pitfall is crucial for accurate PET/CT reporting.

CANCERS (2022)

Add to Collection

Article Pharmacology & Pharmacy

Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT

Kevin Zwirtz et al.

Summary: This study aimed to compare different methods for predicting response to PRRT and overall survival in patients with neuroendocrine tumors. The results showed significant differences in predictive abilities among different assessment methods. Baseline ZP and ZPnormalized were found to be the best parameters for predicting lesion progression after three PRRT cycles.

PHARMACEUTICS (2022)

Add to Collection

Review Oncology

Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review

Aman Chauhan et al.

Summary: Neuroendocrine tumors (NETs) are increasingly common, and the treatment options for advanced NETs are evolving rapidly. However, there is limited data on how different treatments should be sequenced. This review assesses clinical trial data and provides expert perspectives on treatment sequencing for various clinical scenarios. The best practices provided in this review can be helpful for clinicians considering treatment options for their patients with advanced NETs.

CANCERS (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

18F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study

Tina Binderup et al.

Summary: This study demonstrated the long-term prognostic value of F-18-FDG PET imaging for risk stratification of neuroendocrine neoplasms, surpassing tumor grading. F-18-FDG PET is able to differentiate low- and high-risk groups even within G1 and G2 tumors, providing valuable information for treatment selection and risk assessment in NEN patients.

JOURNAL OF NUCLEAR MEDICINE (2021)

Add to Collection

Review Oncology

Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis

Jonathan Strosberg et al.

Summary: Re-treatment with Lu-177-PRRT showed encouraging median PFS in patients with NETs, with a safety profile similar to initial PRRT.

CANCER TREATMENT REVIEWS (2021)

Add to Collection

Article Oncology

177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial

Jonathan R. Strosberg et al.

Summary: The NETTER-1 trial did not show a significant improvement in median overall survival with Lu-177-Dotatate treatment compared to high-dose long-acting octreotide, however, there was an 11.7 month difference which could be considered clinically relevant. No new safety signals were reported during long-term follow-up.

LANCET ONCOLOGY (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE

Claudia Ortega et al.

Summary: This study demonstrated that quantitative PET parameters can predict therapy response and progression-free survival (PFS) in patients with neuroendocrine tumors. Specific parameters included SUVmax and liver tumor volume parameters for marker lesions, as well as liver SUVmax and kurtosis parameters.

JOURNAL OF NUCLEAR MEDICINE (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker

David L. Chan et al.

Summary: The NETPET score, utilizing uptake of both F-18-FDG and somatostatin receptor imaging agents, has been shown to be a prognostic biomarker in bronchial NENs, highlighting its significance in prognostic assessment.

JOURNAL OF NUCLEAR MEDICINE (2021)

Add to Collection

Article Endocrinology & Metabolism

Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome

Wouter T. Zandee et al.

Summary: PRRT treatment effectively reduced diarrhea and flushing in patients with carcinoid syndrome, making it a possible option for symptomatic treatment in cases where somatostatin analogs are not fully controlling symptoms.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

Add to Collection

Review Chemistry, Medicinal

Combination Therapies with PRRT

Anna Yordanova et al.

Summary: PRRT is a successful targeted radionuclide therapy for NETs. Combination therapies are anticipated to have synergistic effects and balanced toxicity profile. Few studies have evaluated the effects of combination therapies with PRRT, mainly phase I/II trials.

PHARMACEUTICALS (2021)

Add to Collection

Article Medicine, General & Internal

Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States

Zihan Xu et al.

Summary: The study analyzed epidemiologic and survival data of 43,751 patients with GEP-NETs from 1975 to 2015, finding a continuous increase in the incidence and prevalence of GEP-NETs, especially among patients with rectal GEP-NETs. Additionally, a nomogram with 5 prognostic parameters was established to accurately quantify the risk of death among patients with GEP-NETs, showing satisfactory clinical practicality.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Endocrinology & Metabolism

Peptide Receptor Radionuclide Therapy With Lu-177-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome

Wouter T. Zandee et al.

Summary: PRRT with Lu-177-DOTATATE effectively reduced diarrhea and flushing in patients with carcinoid syndrome, showing potential as a symptomatic treatment option for patients whose symptoms are not well controlled with somatostatin analogs.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE

Josephine Graf et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest

Lisa Bodei et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy

Thomas A. Hope et al.

JOURNAL OF NUCLEAR MEDICINE (2020)

Add to Collection

Article Oncology

Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a US-Based Neuroendocrine Tumor Cohort

Jason M. Heckert et al.

ONCOLOGIST (2020)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?

Alexander R. Haug

EJNMMI RESEARCH (2020)

Add to Collection

Review Oncology

Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy A Systematic Review

Mohamad Bassam Sonbol et al.

JAMA ONCOLOGY (2020)

Add to Collection

Review Medicine, General & Internal

Prevention and Management of Hormonal Crisis during Theragnosis with LU-DOTA-TATE in Neuroendocrine Tumors. A Systematic Review and Approach Proposal

Maria Isabel del Olmo-Garcia et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Article Gastroenterology & Hepatology

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors

Thorvardur R. Halfdanarson et al.

PANCREAS (2020)

Add to Collection

Article Oncology

Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy

Daphne M. Huizing et al.

CANCER IMAGING (2020)

Add to Collection

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

Updates to the Appropriate-Use Criteria for Somatostatin Receptor PET

Thomas A. Hope

JOURNAL OF NUCLEAR MEDICINE (2020)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden

Thomas A. Hope et al.

JOURNAL OF NUCLEAR MEDICINE (2019)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

Therapy With 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors

A. Tuba Kendi et al.

AMERICAN JOURNAL OF ROENTGENOLOGY (2019)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Quality of life in patients with midgut NET following peptide receptor radionuclide therapy

Milka Marinova et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE

Thomas A. Hope et al.

JOURNAL OF NUCLEAR MEDICINE (2019)

Add to Collection

Review Oncology

Management of carcinoid syndrome: a systematic review and meta-analysis

Johannes Hofland et al.

ENDOCRINE-RELATED CANCER (2019)

Add to Collection

Article Endocrinology & Metabolism

Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors

Wouter T. Zandee et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy

Lisa Bodei et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)

Add to Collection

Article Oncology

Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial

Jonathan Strosberg et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression

Martin H. Cherk et al.

CANCER IMAGING (2018)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors

Camilla B. Johnbeck et al.

JOURNAL OF NUCLEAR MEDICINE (2017)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Predictive Value of Asphericity in Pretherapeutic [111In]DTPA-Octreotide SPECT/CT for Response to Peptide Receptor Radionuclide Therapy with [177Lu]DOTATATE

Christoph Wetz et al.

MOLECULAR IMAGING AND BIOLOGY (2017)

Add to Collection

Article Oncology

Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity

Rudolf A. Werner et al.

ONCOTARGET (2017)

Add to Collection

Article Oncology

Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate

Tessa Brabander et al.

ENDOCRINE-RELATED CANCER (2017)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

68Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis

Michael M. Graham et al.

JOURNAL OF NUCLEAR MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

J. Strosberg et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Gastroenterology & Hepatology

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors

Jonathan R. Strosberg et al.

PANCREAS (2017)

Add to Collection

Article Oncology

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

Arvind Dasari et al.

JAMA ONCOLOGY (2017)

Add to Collection

Review Oncology

Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus

Andrew Kennedy et al.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2017)

Add to Collection

Article Oncology

Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0, Tyr3] octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors

Tessa Brabander et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors

L. Bodei et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis

Stephen A. Deppen et al.

JOURNAL OF NUCLEAR MEDICINE (2016)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors

Brian P. Riff et al.

CLINICAL NUCLEAR MEDICINE (2015)

Add to Collection

Review Oncology

Consensus on biomarkers for neuroendocrine tumour disease

Kjell Oberg et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Somatostatin Receptor Imaging with 68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation

Michael S. Hofman et al.

RADIOGRAPHICS (2015)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

Lisa Bodei et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors

C. Kratochwil et al.

MOLECULAR IMAGING AND BIOLOGY (2015)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)

G. Kong et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification

Irina Velikyan et al.

JOURNAL OF NUCLEAR MEDICINE (2014)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: Is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC?

M. Oe. Oeksuez et al.

DIAGNOSTIC AND INTERVENTIONAL IMAGING (2014)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT

A. Kroiss et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)

Add to Collection

Article Multidisciplinary Sciences

The Identification of Gut Neuroendocrine Tumor Disease by Multiple Synchronous Transcript Analysis in Blood

Irvin M. Modlin et al.

PLOS ONE (2013)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Ga-68 DOTA-NOC Uptake in the Pancreas Pathological and Physiological Patterns

Yodphat Krausz et al.

CLINICAL NUCLEAR MEDICINE (2012)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI

F. L. Giesel et al.

EUROPEAN JOURNAL OF RADIOLOGY (2012)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours?

Akram Al-Ibraheem et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors

Thorsten D. Poeppel et al.

JOURNAL OF NUCLEAR MEDICINE (2011)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Comparison of gadolinium-EOB-DTPA-enhanced and diffusion-weighted liver MRI for detection of small hepatic metastases

Kotaro Shimada et al.

EUROPEAN RADIOLOGY (2010)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor-Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine Tumors

Alexander R. Haug et al.

JOURNAL OF NUCLEAR MEDICINE (2010)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions

Ahmed Ba-Ssalamah et al.

EUROPEAN RADIOLOGY (2009)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor-Mediated Radionuclide Therapy

Michael Gabriel et al.

JOURNAL OF NUCLEAR MEDICINE (2009)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE:: the role of associated risk factors

Lisa Bodei et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)

Add to Collection

Article Oncology

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria

Haesun Choi et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting

JC Reubi et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.